6
Capture, Convert, and Conquer: Innovations Wanted for the “Best CO₂ Utilisation 2025” Innovation Award
One document
more
Stories about Chemie
Press release: Aurubis investing € 40 million in more independent and efficient production in Lünen
One documentmoreGrünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
moreLAUDA DR. R. WOBSER GMBH & CO. KG
40th work anniversary at the world market leader
more- 5
Advanced Recycling Conference 2024 – Driving Innovation in Sustainable Materials Management
One documentmore Technische Universität München
Significant Extension of Zinc Battery Lifespan
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM Researchers Develop New Chemical Method for Improved Energy Storage Significant Extension of Zinc Battery Lifespan - Improvement to several hundred thousand charge cycles - Protective layer for zinc anode - Important result in basic research - Large-scale engineering implementation still pending The transition to renewable energy requires efficient methods for storing large ...
more
First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
moreObrist Group: Modern Forest is 30 Times Better for the Climate Than Traditional Forests
more- 4
Press Release - hubergroup showcases Innovative Solutions at EURASIA PACKAGING FAIR 2024
One documentmore Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
moreObrist Group Now Open for Institutional Investors
more- 6
Press Release - hubergroup is Cradle to Cradle certified for the fourth time in a row
One documentmore
PCC BakkiSilicon hf. receives ISCC Carbon Footprint Certification for critical raw material silicon / PCC subsidiary becomes first silicon producer to receive ISCC certification for carbon footprint
more- 5
Advanced Recycling Conference 2024: New Focus Areas and Innovative Program Announced
One documentmore - 4
CO₂-based Fuels and Chemicals Conference 2025 – Call for Abstracts and Posters
One documentmore Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...
moreTechnische Universität München
What gave the first molecules their stability?
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE New insights into the origins of life What gave the first molecules their stability? • Until now, it was unclear how complex molecules could survive in the primordial soup• Unstable RNA molecules are stabilized by double strands • RNAs may be able to form their own complementary strand The origins of life remain a major mystery. How were complex molecules able to form and ...
moreGrünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®
Aachen, Germany (ots) - - Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. - With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). - Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly ...
more
Hydrogenious LOHC Technologies GmbH
IPCEI: Hydrogenious LOHC receives multi-million grant for Green Hydrogen @ Blue Danube
more- 3
Press release: Largest planned maintenance shutdown at Aurubis Hamburg plant successfully concluded
One documentmore - 7
Press Release - Eurosyn announces Strategic Partnership with hubergroup Chemicals
One documentmore - 10
Gerresheimer: New pictures available
more LAUDA DR. R. WOBSER GMBH & CO. KG
5ACHEMA 2024: LAUDA Looks Back on a Successful Exhibition
moreAn era comes to an end: Last piece of coal fired at Oberkirch combined heat and power plant
more
- 2
Press release: More strategic metals for Europe: Aurubis commissions modernized tankhouse in Lünen
One documentmore - 2
Biesterfeld Group acquires Aerontec and expands its presence in Africa
more - 3
Red Dot Design Award for LAMILUX Modular Glass Skylight MS78
One documentmore Gerresheimer expands capacities for Medical Systems in the USA
moreTechnische Universität München
Multi-purpose mucus - What mucins can do in medicine
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE What mucins can do in medicine Multi-purpose mucus They are in our eyes, on our tongues, and in our stomachs: Protective layers of mucus, a slime consisting primarily of mucins. These are molecules which bind water to form a natural lubricant. Researchers at the Technical University of Munich (TUM) use them to develop coatings for contact lenses and intubation tubes, healing ...
more- 5
Exploring the Future of Advanced Recycling: Early Bird Tickets Now Available
One documentmore
Previous12345678910Next